These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18471921)

  • 1. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.
    Rawat A; Majumder QH; Ahsan F
    J Control Release; 2008 Jun; 128(3):224-32. PubMed ID: 18471921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.
    Gupta V; Ahsan F
    Int J Pharm; 2011 Jul; 413(1-2):51-62. PubMed ID: 21530623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of additives and processing parameters on the initial burst release of protein from poly(lactic-co-glycolic acid) microspheres.
    Zheng CH; Gao JQ; Liang WQ; Yu HY; Zhang YL
    PDA J Pharm Sci Technol; 2006; 60(1):54-9. PubMed ID: 17089678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
    Thomas C; Gupta V; Ahsan F
    Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension.
    Gupta V; Rawat A; Ahsan F
    J Pharm Sci; 2010 Apr; 99(4):1774-89. PubMed ID: 19894275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
    Patel B; Gupta V; Ahsan F
    J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin loaded pH-sensitive microparticles.
    Meissner Y; Ubrich N; Ghazouani FE; Maincent P; Lamprecht A
    Int J Pharm; 2007 Apr; 335(1-2):147-153. PubMed ID: 17150317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).
    Gupta V; Davis M; Hope-Weeks LJ; Ahsan F
    Pharm Res; 2011 Jul; 28(7):1733-49. PubMed ID: 21626061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.
    Thomas C; Gupta V; Ahsan F
    Pharm Res; 2010 May; 27(5):905-19. PubMed ID: 20232117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.
    Yang T; Hussain A; Bai S; Khalil IA; Harashima H; Ahsan F
    J Control Release; 2006 Oct; 115(3):289-97. PubMed ID: 17023085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
    Nasr M; Awad GA; Mansour S; Taha I; Al Shamy A; Mortada ND
    Eur J Pharm Biopharm; 2011 Nov; 79(3):601-11. PubMed ID: 21827854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalable lactose-based dry powder formulations of low molecular weight heparin.
    Bai S; Gupta V; Ahsan F
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):97-104. PubMed ID: 19778265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).
    Rashid J; Patel B; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
    J Control Release; 2017 Mar; 250():96-106. PubMed ID: 28185800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Molecular-Weight Heparin-Coated and Montelukast-Filled Inhalable Particles: A Dual-Drug Delivery System for Combination Therapy in Asthma.
    Patel B; Rashid J; Gupta N; Ahsan F
    J Pharm Sci; 2017 Apr; 106(4):1124-1135. PubMed ID: 28057540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
    Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
    Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin.
    Yang T; Nyiawung D; Silber A; Hao J; Lai L; Bai S
    AAPS PharmSciTech; 2012 Dec; 13(4):1309-18. PubMed ID: 23054983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method.
    He J; Zhou Z; Fan Y; Zhou X; Du H
    J Microencapsul; 2011; 28(8):763-70. PubMed ID: 22034953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes.
    De Rosa G; Quaglia F; La Rotonda MI; Appel M; Alphandary H; Fattal E
    J Pharm Sci; 2002 Mar; 91(3):790-9. PubMed ID: 11920765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.
    Patel B; Gupta N; Ahsan F
    J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):12-20. PubMed ID: 24286441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brush-like branched biodegradable polyesters, part III. Protein release from microspheres of poly(vinyl alcohol)-graft-poly(D,L-lactic-co-glycolic acid).
    Frauke Pistel K; Breitenbach A; Zange-Volland R; Kissel T
    J Control Release; 2001 May; 73(1):7-20. PubMed ID: 11337055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.